Drug Trial Radar · NCT01631214
Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis
Last checked: Nov 20, 2026Latest source record: Feb 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,093
Actual
Start
May 4, 2012
Primary completion
Feb 27, 2017
Study completion Jun 29, 2017
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Jun 29, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 55 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if treatment is effective in preventing fractures in women with postmenopausal osteoporosis.
Conditions
- Postmenopausal Women With Osteoporosis
Interventions
RomosozumabBiological
Romosozumab 210 mg administered by subcutaneous injection once a month during the double-blind treatment phase.
AlendronateDrug
Alendronate 70 mg tablet taken once a week
Placebo to RomosozumabDrug
Administered by subcutaneous injection once a month during the double-blind treatment phase.
Placebo to AlendronateDrug
Matching placebo tablet taken once a week during the double-blind treatment phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With New Vertebral Fractures Through Month 24Time frame: 24 months
- Percentage of Participants With a Clinical Fracture at the Primary AnalysisTime frame: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).
Locations
316 sites in 42 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Peoria, Arizona
Research Site
Phoenix, Arizona
Research Site
Scottsdale, Arizona
Research Site
Downey, California
Research Site
Greenbrae, California
Research Site
Los Angeles, California
Research Site
South Lake Tahoe, California
Research Site
Tustin, California
Research Site
Walnut Creek, California
Research Site
Lakewood, Colorado
Research Site
Fort Lauderdale, Florida
Research Site
Miami, Florida
Research Site
Stuart, Florida
Research Site
West Palm Beach, Florida
Research Site
Gainesville, Georgia
Research Site
Maywood, Illinois
Research Site
Quincy, Illinois
Research Site
Indianapolis, Indiana
Research Site
Bethesda, Maryland
Research Site
Boston, Massachusetts
Research Site
Detroit, Michigan
Research Site
St Louis, Missouri
Research Site
Las Vegas, Nevada
Research Site
Las Cruces, New Mexico
Research Site
Great Neck, New York
Research Site
Bismarck, North Dakota
Research Site
Pittsburgh, Pennsylvania
Research Site
Wyomissing, Pennsylvania
Research Site
Richmond, Virginia
Research Site
Port Angeles, Washington
Research Site
Madison, Wisconsin
Research Site
Buenos Aires, Argentina
Research Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Research Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Research Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Research Site
Mar del Plata, Buenos Aires, Argentina
Research Site
Quilmes, Buenos Aires, Argentina
Research Site
Córdoba, Córdoba Province, Argentina
Research Site
Darlinghurst, New South Wales, Australia
Showing 40 of 316 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.